Insider trade

Officer received an award of 40K EW derivative securities

Traded May 7, 2026 · Filed May 9, 2026

Edwards LifesciencesEW

40K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 7, 2026
Reporting period: Not applicable
Filed with the SEC: May 9, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001225208-26-005045
Filed / recorded

May 9, 2026, 1:16 AM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

Edwards Lifesciences Corp

Issuer CIK

1099800

Ticker

EW

Reporting person

Daniel J. Lippis

Relationship

Officer

Officer title

CVP, TAVR

Security

Employee Stock Option (Right to Acquire)

Table

Derivative (Table II)

Transaction date

May 7, 2026

Transaction code

A

Shares / units

39,900

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

39,900

Ownership form

Direct

Amendment

No

Footnotes from the filing

These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.